Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

260 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study.
Eisenberger U, Budde K, Lehner F, Sommerer C, Reinke P, Witzke O, Wüthrich RP, Stahl R, Heller K, Suwelack B, Mühlfeld A, Hauser IA, Nadalin S, Porstner M, Arns W; ZEUS Study Investigators. Eisenberger U, et al. Among authors: lehner f. BMC Nephrol. 2018 Jun 28;19(1):154. doi: 10.1186/s12882-018-0950-1. BMC Nephrol. 2018. PMID: 29954336 Free PMC article. Clinical Trial.
Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
Lehner F, Budde K, Zeier M, Wüthrich RP, Reinke P, Eisenberger U, Mühlfeld A, Arns W, Stahl R, Heller K, Witzke O, Wolters HH, Suwelack B, Klehr HU, Stangl M, Hauser IA, Nadalin S, Porstner M, May C, Paulus EM, Sommerer C; ZEUS Study Investigators. Lehner F, et al. Transpl Int. 2014 Nov;27(11):1192-204. doi: 10.1111/tri.12411. Epub 2014 Aug 20. Transpl Int. 2014. PMID: 25070687 Free article. Clinical Trial.
Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial.
Sommerer C, Budde K, Zeier M, Wüthrich RP, Reinke P, Eisenberger U, Mühlfeld A, Arns W, Stahl R, Heller K, Wolters HH, Suwelack B, Klehr HU, Hauser IA, Stangl M, Nadalin S, Dürr M, Porstner M, May C, Wimmer P, Witzke O, Lehner F. Sommerer C, et al. Among authors: lehner f. Clin Nephrol. 2016 Apr;85(4):215-25. doi: 10.5414/CN108726. Clin Nephrol. 2016. PMID: 26932178 Clinical Trial.
Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.
Budde K, Zeier M, Witzke O, Arns W, Lehner F, Guba M, Jacobi J, Kliem V, Reinke P, Hauser IA, Vogt B, Stahl R, Rath T, Duerr M, Paulus EM, May C, Porstner M, Sommerer C; HERAKLES Study Group. Budde K, et al. Among authors: lehner f. Nephrol Dial Transplant. 2017 Jun 1;32(6):1060-1070. doi: 10.1093/ndt/gfx075. Nephrol Dial Transplant. 2017. PMID: 28605781 Clinical Trial.
Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
Sommerer C, Duerr M, Witzke O, Lehner F, Arns W, Kliem V, Ackermann D, Guba M, Jacobi J, Hauser IA, Stahl R, Reinke P, Rath T, Veit J, Mehrabi A, Porstner M, Budde K; HERAKLES Study Group. Sommerer C, et al. Among authors: lehner f. Am J Transplant. 2018 Dec;18(12):2965-2976. doi: 10.1111/ajt.14897. Epub 2018 Jun 3. Am J Transplant. 2018. PMID: 29722128 Free article. Clinical Trial.
Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials.
Sommerer C, Witzke O, Lehner F, Arns W, Reinke P, Eisenberger U, Vogt B, Heller K, Jacobi J, Guba M, Stahl R, Hauser IA, Kliem V, Wüthrich RP, Mühlfeld A, Suwelack B, Duerr M, Paulus EM, Zeier M, Porstner M, Budde K; ZEUS and HERAKLES study investigators. Sommerer C, et al. Among authors: lehner f. BMC Nephrol. 2018 Sep 19;19(1):237. doi: 10.1186/s12882-018-1031-1. BMC Nephrol. 2018. PMID: 30231851 Free PMC article.
Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR).
Brakemeier S, Arns W, Lehner F, Witzke O, Vonend O, Sommerer C, Mühlfeld A, Rath T, Schuhmann R, Zukunft B, Kroeger I, Porstner M, Budde K. Brakemeier S, et al. Among authors: lehner f. PLoS One. 2019 Sep 19;14(9):e0222730. doi: 10.1371/journal.pone.0222730. eCollection 2019. PLoS One. 2019. PMID: 31536556 Free PMC article. Clinical Trial.
Effect of everolimus-based drug regimens on CMV-specific T-cell functionality after renal transplantation: 12-month ATHENA subcohort-study results.
Hauser IA, Marx S, Sommerer C, Suwelack B, Dragun D, Witzke O, Lehner F, Schiedel C, Porstner M, Thaiss F, Neudörfl C, Falk CS, Nashan B, Sester M. Hauser IA, et al. Among authors: lehner f. Eur J Immunol. 2021 Apr;51(4):943-955. doi: 10.1002/eji.202048855. Epub 2020 Dec 28. Eur J Immunol. 2021. PMID: 33306229 Free article.
Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.
Budde K, Lehner F, Sommerer C, Arns W, Reinke P, Eisenberger U, Wüthrich RP, Scheidl S, May C, Paulus EM, Mühlfeld A, Wolters HH, Pressmar K, Stahl R, Witzke O; ZEUS Study Investigators. Budde K, et al. Among authors: lehner f. Am J Transplant. 2012 Jun;12(6):1528-40. doi: 10.1111/j.1600-6143.2012.03994.x. Epub 2012 Mar 5. Am J Transplant. 2012. PMID: 22642473 Free article. Clinical Trial.
Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.
Budde K, Lehner F, Sommerer C, Reinke P, Arns W, Eisenberger U, Wüthrich RP, Mühlfeld A, Heller K, Porstner M, Veit J, Paulus EM, Witzke O; ZEUS Study Investigators. Budde K, et al. Among authors: lehner f. Am J Transplant. 2015 Jan;15(1):119-28. doi: 10.1111/ajt.12952. Epub 2014 Dec 17. Am J Transplant. 2015. PMID: 25521535 Free article. Clinical Trial.
260 results